{"id":732272,"date":"2025-02-19T06:50:02","date_gmt":"2025-02-19T06:50:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=732272"},"modified":"2025-02-19T06:50:02","modified_gmt":"2025-02-19T06:50:02","slug":"diabetic-kidney-disease-drugs-market-2034-ema-pdma-fda-approvals-prevalence-clinical-trials-nda-approvals-medication-revenue-statistics-therapies-companies-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/diabetic-kidney-disease-drugs-market-2034-ema-pdma-fda-approvals-prevalence-clinical-trials-nda-approvals-medication-revenue-statistics-therapies-companies-by-delveinsight_732272.html","title":{"rendered":"Diabetic Kidney Disease Drugs Market 2034: EMA, PDMA, FDA Approvals, Prevalence, Clinical Trials, NDA Approvals, Medication, Revenue, Statistics, Therapies, Companies by DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/upload\/2025\/02\/1739882023.jpg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Diabetic Kidney Disease Drugs Market 2034: EMA, PDMA, FDA Approvals, Prevalence, Clinical Trials, NDA Approvals, Medication, Revenue, Statistics, Therapies, Companies by DelveInsight \" src=\"https:\/\/www.abnewswire.com\/upload\/2025\/02\/1739882023.jpg\" alt=\"Diabetic Kidney Disease Drugs Market 2034: EMA, PDMA, FDA Approvals, Prevalence, Clinical Trials, NDA Approvals, Medication, Revenue, Statistics, Therapies, Companies by DelveInsight \" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Diabetic Kidney Disease Drugs Market<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">Diabetic Kidney Disease Companies are Boehringer Ingelheim, Bayer, Curacle Co., Ltd., Pfizer, Mitsubishi Tanabe Pharma, PhytoHealth Corporation, Eli Lilly and Company, Korea Otsuka Pharmaceutical, BioStratum, Fresenius Kabi, and others.<\/div>\n<p style=\"text-align: justify;\">(Albany, USA) DelveInsight&rsquo;s &ldquo;<strong>Diabetic Kidney Disease Market Insights, Epidemiology, and Market Forecast-2034<\/strong>&Prime; report offers an in-depth understanding of the Diabetic Kidney Disease, historical and forecasted epidemiology as well as the Diabetic Kidney Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.<\/p>\n<p style=\"text-align: justify;\">The latest healthcare forecast report offers a detailed examination of Diabetic Kidney Disease, providing valuable insights into revenue trends, prevalence, and the treatment landscape. It explores key statistics, assessing the current and future market size while evaluating the effectiveness and progress of emerging therapies. Additionally, the report covers the clinical trial landscape, outlining ongoing and upcoming studies that are set to influence the future of Diabetic Kidney Disease treatment. This comprehensive resource is essential for understanding market dynamics and evolving therapeutic options in this space.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To Know in detail about the Diabetic Kidney Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/diabetic-kidney-disease-dkd-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" >Diabetic Kidney Disease Market Forecast<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key facts of the Diabetic Kidney Disease Market Report: <\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>The Diabetic Kidney Disease market size was vlaued <strong>~USD 7,200 million in 2023<\/strong> and is anticipated to grow with a significant CAGR during the study period (2020-2034)<\/p>\n<\/li>\n<li>\n<p>Key Diabetic Kidney Disease Companies: <em><strong>Curacle Co., Ltd., Boehringer Ingelheim, Bayer, Pfizer, Mitsubishi Tanabe Pharma, PhytoHealth Corporation, Eli Lilly and Company, Korea Otsuka Pharmaceutical, BioStratum, Fresenius Kabi, and others<\/strong><\/em><\/p>\n<\/li>\n<li>\n<p>Key Diabetic Kidney Disease Therapies: <em><strong>CU01-1001, BI 685509, BAY94-8862, PF-00489791, Canagliflozin, PH3, LY3016859, Probucol, Pyridorin, Ketosteril&reg;, and others<\/strong><\/em><\/p>\n<\/li>\n<li>\n<p>The Diabetic Kidney Disease market is expected to surge due to the disease&rsquo;s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Diabetic Kidney Disease pipeline products will significantly revolutionize the Diabetic Kidney Disease market dynamics.<\/p>\n<\/li>\n<li>\n<p>According to DelveInsight&rsquo;s estimates, the total prevalent cases of diabetes in the 7MM were approximately <strong>82,858,700<\/strong> in 2023, with a projected increase over the study period.<\/p>\n<\/li>\n<li>\n<p>In 2023, the United States had the highest number of diagnosed prevalent cases of diabetic kidney disease (DKD), with roughly <strong>5,141,000 cases<\/strong>.<\/p>\n<\/li>\n<li>\n<p>DKD is predominantly observed in individuals aged 60 and above, accounting for 70% of cases. In the US, age-specific cases of DKD in 2023 were approximately<strong> 1,542,000 in the 18&ndash;59 age group<\/strong> and around <strong>3,600,000 in the 60+ age group<\/strong>.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Diabetic Kidney Disease Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Diabetic Kidney Disease (DKD), also known as diabetic nephropathy, is a serious complication of diabetes that affects kidney function over time. It occurs due to prolonged high blood sugar levels, which damage the kidney&rsquo;s filtration system, leading to protein leakage in the urine (albuminuria) and a gradual decline in kidney function. DKD is a leading cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, significantly impacting patients&#8217; quality of life and increasing healthcare costs.<\/p>\n<p style=\"text-align: justify;\">The condition progresses through five stages, from mild kidney damage to complete kidney failure requiring dialysis or transplantation. Risk factors include poor blood sugar control, hypertension, genetic predisposition, and lifestyle factors such as smoking and obesity. Early diagnosis through routine screening of urine albumin levels and kidney function tests is crucial for managing the disease effectively.<\/p>\n<p style=\"text-align: justify;\">Treatment primarily focuses on controlling blood glucose and blood pressure through medications like SGLT2 inhibitors, ACE inhibitors, and ARBs, which have shown to slow disease progression. Additionally, lifestyle modifications, including a balanced diet, regular exercise, and smoking cessation, play a key role in preventing complications. Ongoing clinical trials and research into novel therapies continue to advance treatment options, aiming to improve outcomes for DKD patients.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get a Free sample for the Diabetic Kidney Disease Market Forecast, Size &amp; Share Analysis Report:<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/diabetic-kidney-disease-dkd-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" >https:\/\/www.delveinsight.com\/report-store\/diabetic-kidney-disease-dkd-market<\/a> <\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Diabetic Kidney Disease Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify;\">The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Diabetic Kidney Disease Epidemiology Segmentation:<\/strong><\/p>\n<p style=\"text-align: justify;\">The Diabetic Kidney Disease market report proffers epidemiological analysis for the study period 2020&ndash;2034 in the 7MM segmented into:<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Total Prevalent Cases of Diabetes in the 7MM<\/p>\n<\/li>\n<li>\n<p>Total Prevalent Cases of DKD in the 7MM<\/p>\n<\/li>\n<li>\n<p>Diagnosed Prevalent Cases of DKD in the 7MM<\/p>\n<\/li>\n<li>\n<p>Age-specific Cases of DKD in the 7MM<\/p>\n<\/li>\n<li>\n<p>Stage-specific Cases of DKD in the 7MM<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download the report to understand which factors are driving Diabetic Kidney Disease epidemiology trends @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/diabetic-kidney-disease-dkd-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" >Diabetic Kidney Disease Epidemiology Forecast<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Diabetic Kidney Disease Drugs Uptake and Pipeline Development Activities<\/strong><\/p>\n<p style=\"text-align: justify;\">The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Diabetic Kidney Disease market or expected to get launched during the study period. The analysis covers Diabetic Kidney Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.<\/p>\n<p style=\"text-align: justify;\">Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.<\/p>\n<p style=\"text-align: justify;\">The report also covers the Diabetic Kidney Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Diabetic Kidney Disease Therapies and Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>CU01-1001: Curacle Co., Ltd.<\/p>\n<\/li>\n<li>\n<p>BI 685509: Boehringer Ingelheim<\/p>\n<\/li>\n<li>\n<p>BAY94-8862: Bayer<\/p>\n<\/li>\n<li>\n<p>PF-00489791: Pfizer<\/p>\n<\/li>\n<li>\n<p>Canagliflozin: Mitsubishi Tanabe Pharma<\/p>\n<\/li>\n<li>\n<p>PH3: PhytoHealth Corporation<\/p>\n<\/li>\n<li>\n<p>LY3016859: Eli Lilly and Company<\/p>\n<\/li>\n<li>\n<p>Probucol: Korea Otsuka Pharmaceutical<\/p>\n<\/li>\n<li>\n<p>Pyridorin: BioStratum<\/p>\n<\/li>\n<li>\n<p>Ketosteril&reg;: Fresenius Kabi<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Discover more about therapies set to grab major Diabetic Kidney Disease market share @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/diabetic-kidney-disease-dkd-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" >Diabetic Kidney Disease Treatment Landscape<\/a> <\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Diabetic Kidney Disease Market Strengths<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Many major companies are investing in different mechanisms of action for the treatment of DKD, peripherally-acting CB1r blockers, IL-33-neutralizing mAb, ETA receptor antagonists, aldosterone synthase inhibitor (ASi), mineralocorticoid receptor (MR) blockers, and others which will boost the DKD market in the future.<\/p>\n<\/li>\n<li>\n<p>A unique trial testing of BI 690517, a selective aldosterone synthase inhibitor along with SGLT2 inhibition, showed positive efficacy, offering the potential for additive kidney benefits while possibly mitigating hyperkalemia risk.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Diabetic Kidney Disease Market Opportunities<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Personalized medicine, considering the genetic and mechanistic variability, will improve renal and cardiovascular protection in diabetic patients with CKD.<\/p>\n<\/li>\n<li>\n<p>The concept of &ldquo;metabolic memory&rdquo; in diabetic patients, where prior exposure to elevated blood glucose levels results in enduring detrimental effects despite glycemic control, opens a window of opportunity to develop genetic interventions such as CRISPR&ndash;Cas editing to potentially erase this memory and offer novel therapeutic avenues for diabetic kidney disease.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Diabetic Kidney Disease Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Study Period: 2020&ndash;2034<\/p>\n<\/li>\n<li>\n<p>Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]<\/p>\n<\/li>\n<li>\n<p>Key Diabetic Kidney Disease Companies: Curacle Co., Ltd., Boehringer Ingelheim, Bayer, Pfizer, Mitsubishi Tanabe Pharma, PhytoHealth Corporation, Eli Lilly and Company, Korea Otsuka Pharmaceutical, BioStratum, Fresenius Kabi, and others<\/p>\n<\/li>\n<li>\n<p>Key Diabetic Kidney Disease Therapies: CU01-1001, BI 685509, BAY94-8862, PF-00489791, Canagliflozin, PH3, LY3016859, Probucol, Pyridorin, Ketosteril&reg;, and others<\/p>\n<\/li>\n<li>\n<p>Diabetic Kidney Disease Therapeutic Assessment: Diabetic Kidney Disease current marketed and Diabetic Kidney Disease emerging therapies<\/p>\n<\/li>\n<li>\n<p>Diabetic Kidney Disease Market Dynamics: Diabetic Kidney Disease market drivers and Diabetic Kidney Disease market barriers<\/p>\n<\/li>\n<li>\n<p>Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter&rsquo;s five forces, BCG Matrix, Market entry strategies<\/p>\n<\/li>\n<li>\n<p>Diabetic Kidney Disease Unmet Needs, KOL&rsquo;s views, Analyst&rsquo;s views, Diabetic Kidney Disease Market Access and Reimbursement<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To know more about Diabetic Kidney Disease companies working in the treatment market, visit @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/diabetic-kidney-disease-dkd-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" >Diabetic Kidney Disease Clinical Trials and Therapeutic Assessment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents <\/strong><\/p>\n<p style=\"text-align: justify;\">1. Diabetic Kidney Disease Market Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary for Diabetic Kidney Disease<\/p>\n<p style=\"text-align: justify;\">3. SWOT analysis of Diabetic Kidney Disease<\/p>\n<p style=\"text-align: justify;\">4. Diabetic Kidney Disease Patient Share (%) Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5. Diabetic Kidney Disease Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">6. Diabetic Kidney Disease Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">7. Diabetic Kidney Disease Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8. Country-Specific Patient Population of Diabetic Kidney Disease<\/p>\n<p style=\"text-align: justify;\">9. Diabetic Kidney Disease Current Treatment and Medical Practices<\/p>\n<p style=\"text-align: justify;\">10. Diabetic Kidney Disease Unmet Needs<\/p>\n<p style=\"text-align: justify;\">11. Diabetic Kidney Disease Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">12. Diabetic Kidney Disease Market Outlook<\/p>\n<p style=\"text-align: justify;\">13. Country-Wise Diabetic Kidney Disease Market Analysis (2020&ndash;2034)<\/p>\n<p style=\"text-align: justify;\">14. Diabetic Kidney Disease Market Access and Reimbursement of Therapies<\/p>\n<p style=\"text-align: justify;\">15. Diabetic Kidney Disease Market Drivers<\/p>\n<p style=\"text-align: justify;\">16. Diabetic Kidney Disease Market Barriers<\/p>\n<p style=\"text-align: justify;\">17. Diabetic Kidney Disease Appendix<\/p>\n<p style=\"text-align: justify;\">18. Diabetic Kidney Disease Report Methodology<\/p>\n<p style=\"text-align: justify;\">19. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">20. Disclaimer<\/p>\n<p style=\"text-align: justify;\">21. About DelveInsight<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight <\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=diabetic-kidney-disease-drugs-market-2034-ema-pdma-fda-approvals-prevalence-clinical-trials-nda-approvals-medication-revenue-statistics-therapies-companies-by-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +14699457679<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/aacr-annual-meeting\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/aacr-annual-meeting<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=diabetic-kidney-disease-drugs-market-2034-ema-pdma-fda-approvals-prevalence-clinical-trials-nda-approvals-medication-revenue-statistics-therapies-companies-by-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Diabetic Kidney Disease Drugs Market Diabetic Kidney Disease Companies are Boehringer Ingelheim, Bayer, Curacle Co., Ltd., Pfizer, Mitsubishi Tanabe Pharma, PhytoHealth Corporation, Eli Lilly and Company, Korea Otsuka Pharmaceutical, BioStratum, Fresenius Kabi, and others. (Albany, USA) DelveInsight&rsquo;s &ldquo;Diabetic Kidney Disease &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/diabetic-kidney-disease-drugs-market-2034-ema-pdma-fda-approvals-prevalence-clinical-trials-nda-approvals-medication-revenue-statistics-therapies-companies-by-delveinsight_732272.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-732272","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/732272","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=732272"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/732272\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=732272"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=732272"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=732272"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}